|
I.V. Kosheleva (1, 3), O.A. Bitkina (2), L.I. Shadyzheva (1), O.V. Andriyakhina (3), A.Yu. Nikolaeva (2), M.N. Fyrnina (2), M.A. Deryavaya (2), K.S. Pershina (2), D.S. Zueva (2), A.A. Tsyganova (2)
On the dermatological aspects of the novel coronavirus infection (COVID-19)
|
№8 / 2021
|
|
I.S. Burashnikova
The rationale for the combined use of genetically engineered biological drugs in patients with COVID-19
|
№8 / 2021
|
|
I.S. Burashnikova
The rationale for re-administration of genetically engineered biological drugs in patients with COVID-19
|
№8 / 2021
|
|
M.N. Surina (1), N.V. Artymuk (1), A.V. Atalyan (2), M. Al-Jefout (3), O.O. Chernova (4)
The new COVID-19 virus and its impact on female sexual dysfunction
|
№6 / 2021
|
|
T.E. Belokrinitskaya (1), N.V. Artymuk (2), O.S. Filippov (3), N.I. Frolova (1)
New coronavirus infection COVID-19 in pregnant women: epidemiology, course, outcomes, prevention options
|
№6 / 2021
|
|
E.Yu. Trushina, E.M. Kostina, E.A. Orlova
Patients with bronchial asthma who have undergone COVID-19
|
№5 / 2021
|
|
E.A. Orlova, E.M. Kostina, E.Yu. Trushina
Experience of SLIT in patients with bronchial asthma through the prism of the coronavirus infection pandemic
|
№5 / 2021
|
|
A.V. Veselov
The structure of the mRNA molecule in vaccines for the prevention of SARS-CoV-2 infection – not so simple
|
№5 / 2021
|
|
I.V. Kosheleva (1, 3), O.A. Bitkina (2), L.I. Shadyzheva (1), A.Yu. Nikolaeva (2), O.V. Andriyakhina (3), O.A. Pankova (2), E.S. Udalova (2), A.A. Tsyganova (2)
Skin lesions associated with new coronavirus infection (COVID-19)
|
№8 / 2020
|
|
Yu.G. Belotserkovskaya, A.I. Sinopalnikov
COVID-19: lessons we are learning today (as of April 27, 2020)
|
№5 / 2020
|
|
D.A. Sychev (1), K.B. Mirzaev (1), D.V. Ivashchenko (1), Yu.Yu. Kiselev (2), V.A. Otdelenov (1), A.V. Kryukov (1), V.M. Tsvetov (3), K.A. Zagorodnikova (4), A.V. Matveev (1), S.V. Glagolev (5)
“PharmaCOVID” – information center for pharmacotherapy of patients with new coronavirus infection COVID-19
|
№5 / 2020
|
Русский
